ACTR-61. LONG-TERM ANALYSES OF THE NOA-08 RANDOMIZED PHASE III TRIAL

ABSTRACT: Abstract

BACKGROUND

Optimal treatment and role of O6-methylguanine DNA-methyl transferase (MGMT) status in elderly patients is still not defined.

METHODS

This is the long-term update (LT) of the NOA-08 trial (NCT01502241) that compared efficacy and safety of RT to TMZ in elderly patients with anaplastic astrocytoma (AA) or glioblastoma (GB) using overall survival (OS) as primary endpoint and event-free survival (EFS) as well as efficacy according to MGMT status as major secondary endpoints. FINDINGS: In the LT with a data cut-off Apr 1 2018 median OS was 8·2 [7·0–10·0] months for TMZ treatment versus 9·4 [8·1–10·4] months for RT; hazard ratio (HR)=0·93 (95% CI: 0·76-1·15)] of TMZ versus RT did not differ between both arms. Also, median EFS [3·4 [3·2–4·1] months versus 4·6

SUBMITTER: Kessler T 

PROVIDER: S-EPMC6216462 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature